Cytokine Reduction in the Treatment of Joint Conditions
Author Information
Author(s): J. D. Sipe, J. Martel-Pelletier, I. G. Otterness, J.-P. Pelletier
Primary Institution: Department of Biochemistry, Boston University School of Medicine; Rheumatic Disease Unit, Notre-Dame Hospital Research Center; Department of Immunology and Infectious Diseases, Pfizer, Inc.
Hypothesis
Can cytokine modification effectively treat joint conditions like rheumatoid arthritis and osteoarthritis?
Conclusion
Cytokine inhibitors show promise in treating arthritis, but long-term clinical trials are needed to confirm their effectiveness.
Supporting Evidence
- Cytokines like IL-1, IL-6, and TNF are involved in joint destruction.
- Blocking cytokines may reduce inflammation and joint damage.
- Early clinical trials of cytokine inhibitors show promising results.
Takeaway
This study looks at how certain proteins called cytokines can make joint diseases worse, and how blocking them might help people feel better.
Methodology
The review discusses the role of cytokines in joint destruction and potential therapeutic strategies to inhibit their effects.
Limitations
The review is based on existing literature and does not present new experimental data.
Want to read the original?
Access the complete publication on the publisher's website